Malene Brondberg
Direktor/Vorstandsmitglied bei PHOTOCURE ASA
Vermögen: 3 063 $ am 30.04.2024
Aktive Positionen von Malene Brondberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PHOTOCURE ASA | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Malene Brondberg
Ehemalige bekannte Positionen von Malene Brondberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
THOR MEDICAL | Vorstandsvorsitzender | 26.08.2022 | 01.02.2023 |
Finanzdirektor/CFO | 01.05.2020 | 01.02.2023 | |
Investor Relations Kontakt | 01.02.2018 | 26.08.2022 | |
Public Communications Contact | 01.02.2018 | 01.05.2020 | |
ABG Sundal Collier ASA
ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Direktor der Forschung - Eigenkapital | - | - |
ABG SUNDAL COLLIER HOLDING ASA | Corporate Officer/Principal | 10.06.2010 | - |
Ausbildung von Malene Brondberg
University of Aalborg | Graduate Degree |
Statistik
International
Norwegen | 5 |
Dänemark | 2 |
Operativ
Corporate Officer/Principal | 1 |
Director of Research - Equity | 1 |
Chief Executive Officer | 1 |
Sektoral
Finance | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABG SUNDAL COLLIER HOLDING ASA | Finance |
PHOTOCURE ASA | Health Technology |
Private Unternehmen | 2 |
---|---|
ABG Sundal Collier ASA
ABG Sundal Collier ASA Investment Banks/BrokersFinance Part of ABG Sundal Collier Holding ASA, ABG Sundal Collier ASA provides brokerage services. The company is based in Oslo, Norway. The Norwegian company was founded in 2001. Peter Straume has been the CEO of the company since 2020. | Finance |
Nordic Nanovector ASA
Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
- Börse
- Insiders
- Malene Brondberg
- Erfahrung